Pharmacological treatment of schizophrenia and co-occurring substance use disorders

CNS Drugs

Volumn 22, Issue 11, 2008, Pages 903-916

  Smelson, David A ^a,b   Dixon, Lisa ^c,d   Craig, Thomas ^e   Remolina, Stephen ^f   Batki, Steven L ^a,g,h   Niv, Noosha ⁱ   Owen, Richard ^j  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^c DEPARTMENT OF VETERANS AFFAIRS   (United States)

^d UNIVERSITY OF MARYLAND   (United States)

^e AMERICAN PSYCHIATRIC ASSOCIATION   (United States)

^f DEPARTMENT OF VETERANS AFFAIRS   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j CENTRAL ARKANSAS VETERANS HEALTHCARE SYSTEM   (United States)

more..

Author keywords

Alcoholism, treatment; Aldehyde dehydrogenase inhibitors, therapeutic use; Antipsychotics, therapeutic use; Aripiprazole, therapeutic use; Buprenorphine, therapeutic use; Clozapine, therapeutic use; Cocaine abuse, treatment; Cognitive behavioural therapy

Indexed keywords

ACAMPROSATE; ARIPIPRAZOLE; BUPRENORPHINE; CARBAMAZEPINE; CLOZAPINE; DESIPRAMINE; DISULFIRAM; HALOPERIDOL; IMIPRAMINE; METHADONE; NALTREXONE; NEUROLEPTIC AGENT; OLANZAPINE; OPIATE; PLACEBO; QUETIAPINE; RISPERIDONE; ZIPRASIDONE; ZUCLOPENTHIXOL;

ALCOHOLISM; CLINICAL TRIAL; COCAINE DEPENDENCE; COGNITIVE THERAPY; COMORBIDITY; DRUG DEPENDENCE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FOOD AND DRUG ADMINISTRATION; HUMAN; MENTAL DISEASE; MOTIVATION; PRIORITY JOURNAL; PROGNOSIS; PSYCHOSOCIAL CARE; REVIEW; SCHIZOPHRENIA; SUBSTANCE ABUSE; TREATMENT OUTCOME; UNITED STATES;

ALCOHOLISM; ANTIPSYCHOTIC AGENTS; CLINICAL TRIALS AS TOPIC; HUMANS; OPIOID-RELATED DISORDERS; SCHIZOPHRENIA; SUBSTANCE-RELATED DISORDERS; TREATMENT OUTCOME;

EID: 53549116465     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200822110-00002     Document Type: Review

References (91)

1. Gupta S, Hendricks S, Kenkel AM, et al. Relapse in schizophrenia: is there a relationship to substance abuse. Schizophr Res 1996; 20: 153-6
2. Green AI, Salomon MS, Brenner MJ, et al. Treatment of schizophrenia and comorbid substance use disorder. Curr Drug Targets CNS Neurol Disord 2002; 1: 129-39
3. Regier DA, Farmer ME, Rae DS, et al. Comorbidity of mental disorders with alcohol and other drug abuse. JAMA 1990; 264: 2511-8
4. Lasser K, Wesley BJ, Woolhandler S, et al. Smoking and mental illness: a population-based prevalence study. JAMA 2000; 284: 2606-10
5. Green AI, Schildkraut JJ. Should clozapine be a first-line treatment for schizophrenia? The rationale for a double-blind clinical trial in first-episode patients. Harv Rev Psychiatry 1995 May-Jun; 3 (1): 1-9
6. Ziedonis D, Williams JM, Smelson D. Serious mental illness and tobacco addiction: a model program to address this common but neglected issue. Am J Med Sci 2003; 326 (4): 223-30
7. Green AI, Tohen MF, Hamer RM, et al. First episode schizophrenia-related psychosis and substance use disorders: acute response to olanzapine and haloperidol. Schizophr Res 2004 Feb 1; 66 (2-3): 125-35
8. Green AI. Schizophrenia and comorbid substance use disorder: effects of antipsychotics. J Clin Psychiatry 2005; 66 Suppl. 6: 21-6
9. Owen RR, Fischer EP, Booth EM, et al. Medication noncompliance and substance abuse among patients with schizophrenia. Psychiatric Serv 1996; 47: 853-8
10. Smelson D, Tunis SL, Nyhuis AW, et al. Substance use and antipsychotic treatment discontinuation in a 1-year randomized open label antipsychotic trial for schizophrenia. J Clin Psychopharmacol 2006 Dec; 26 (6): 666-7
11. Serper MR, Alpert M, Richardson NA, et al. Clinical effects of recent cocaine use on patients with acute schizophrenia. Am J Psychiatry 1995; 52: 1464-9
12. Soyka M, Albus M, Immler B, et al. Psychopathology in dual diagnosis and non-addicted schizophrenics: are there differences? Eur Arch Psychiatry Clin Neurosci 2001; 251: 232-8
13. Margolese HC, Malchy L, Negrete JL, et al. Drug and alcohol use among patients with schizophrenia and related psychosis: levels and consequences. Schizophr Res 2004 April; 67 (2-3): 157-66
14. Swofford CD, Scheller-Gilkey G, Miller AH, et al. Double jeopardy: schizophrenia and substance use. Am J Drug Alcohol Abuse 2000 Aug; 26 (3): 343-53
15. Miles H, Johnson S. Characteristics of subgroups of individuals with psychotic illness and a comorbid substance use disorder. Psychiatr Serv 2003; 54: 554-61
16. Potvin S, Stip E, Roy JY. Clozapine, quetiapine and olanzapine among addicted schizophrenic patients: towards testable hypothesis. Int Clin Psychopharmacol 2003; 18 (3): 121-32
17. Carol G, Smelson DA, Losonczy MF, et al. Alcohol and drug abuse: a preliminary investigation of cocaine craving among persons with and without schizophrenia. Psychiatr Serv 2001: 52; 1029-31
18. Smelson DA, Losonczy M, Kaune M, et al. Risperidone decreases cue-elicited craving and relapses in withdrawn cocaine-dependent schizophrenics [abstract]. Schizophr Res 2002; 53: 160
19. Green AI, Noordsy DL, Brunett MF, et al. Substance abuse and schizophrenia: pharmacotherapeutic intervention. J Subst Abuse Treat 2008; 34 (1): 61-71
20. Green AI. Pharmacotherapy for schizophrenia and co-occurring substance use disorders. Neurotox Res 2007 Jan; 11 (1): 33-40
21. Green AI, Drake RE, Brunette MF, et al. Schizophrenia and co-occurring substance use disorder. Am J Psychiatry 2007 Mar; 164 (3): 402-8
22. Green AI, Brown ES. Comorbid schizophrenia and substance abuse. J Clin Psychiatry 2006 Sep; 67 (9): e08
23. Green AI. Treatment of schizophrenia and comorbid substance abuse: pharmacologic approaches. J Clin Psychiatry 2006; 67 Suppl. 7: 31-5; quiz 36-7
24. Khantzian EJ. The self-medication hypothesis of addictive disorders: focus on heroin and cocaine dependence. Am J Psychiatry 1985; 142: 1259-64
25. Brunette MF, Mueser KT, Xie H, et al. Relationships between symptoms of schizophrenia and substance abuse. J Nerv Ment Dis 1997; 185 (1): 13-20
26. Blanchard JJ, Brown SA, Horan WP, et al. Substance use disorders in schizophrenia: review, integration, and a proposed model. Clin Psychol Rev 2000 Mar; 20 (2): 207-34
27. Blanchard JJ, Mueser KT, Bellack AS. Anhedonia, positive and negative affect and social functioning in schizophrenia. Schizophr Bull 1998; 24 (3): 413-24
28. Blanchard JJ, Squires D, Henry T, et al. Examining an affect regulation model of substance abuse in schizophrenia: the role of traits and coping. J Nerv Ment Dis 1999 Feb; 187 (2): 72-9
29. Green AI, Zimmet SV, Strous RD, et al. Clozapine for comorbid substance use disorder and schizophrenia: do patients have a reward-deficiency syndrome that can be ameliorated by clozapine. Harv Rev Psychiatry 1999; 6: 287-96
30. Boileau I, Assaad JM, Pihl RO, et al. Alcohol promotes dopamine release in the human nucleus accumbens. Synapse 2003 Sep 15; 49 (4): 223-31
31. Schreckenberger M, Amberg R, Scheurich A, et al. Acute alcohol effects on neuronal processing: striatal reward system and inhibitory sensory interactions under acute ethanol challenge. Neuropsychopharmacology 2004 Aug; 29 (8): 1527-37
32. Weiss RD, Greenfield SF, Najavits LM, et al. Medication compliance among patients with bipolar disorder and substance use disorder. J Clin Psychiatry 1998; 59: 172-4
33. Green AI. Pharmacotherapy for schizophrenia and co-occurring use disorders. Neurotox Res 2007 Jan; 11 (1): 33-40
34. Ziedonis D, Smelson D, Rosenthal R, et al. Improving the care of individuals with schizophrenia and substance abuse disorders. J Psychiatr Pract 2005; 11 (5): 1-25
35. Ventura J, Green MF, Shaner A, et al. Training and quality assurance with the brief psychiatric rating scale: "the drift buster". Int J Methods Psychiatr Res 1993; 3: 221-44
36. National Institute of Mental Health. CGI: clinical global impressions. In: Guy W, Bonato RR, editors. Manual for the ECDEU assessment battery. 2nd revised ed. Chevy Chase (MD): National Institute of Mental Health, 1970: 12-1-6
37. Kay SR, Fiszbein A, Opler L. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13 (2): 261-76
38. Andreasen NC. Negative symptoms in schizophrenia. Arch Gen Psychiatry 1982; 39: 784-8
39. Sayers SL, Campbell EC, Kondrich J. Cocaine abuse in schizophrenic patients treated with olanzapine versus haloperidol. J Nerv Ment Dis 2005 June; 193 (6): 379-86
40. Smelson DA, Ziedonis D, Williams J, et al. The efficacy of olanzapine for decreasing cue-elicited craving in individuals with schizophrenia and cocaine dependence. J Clin Psycopharmacology 2006 Feb; 26 (1): 9-12
41. Smelson DA, Losonczy MF, Davis CW, et al. Risperidone decreases craving and relapses in individuals with schizophrenia and cocaine dependence. Can J Psychiatry 2002; 47: 671-5
42. Stuyt EB, Sajbel TA, Allen MH. Differing effects of antipsychotic medications on substance abuse treatment patients with co-occuring psychotic and substance abuse disorders. Am J Addict 2006 Mar-Apr; 15 (2): 166-73
43. Petrakis IL, Leslie D, Finney JW, et al. Atypical anti-psychotic medication and substance use-related outcomes in the treatment of schizophrenia. Am J Addict 2006 Jan-Feb; 15 (1): 44-9
44. Green AI, Burgess ES, Dawson R, et al. Alcohol and cannabis use in schizophrenia: effects of clozapine vs risperidone. Schizophr Res 2003; 60: 81-5
45. Akerele E, Levin FR. Comparison of olanzapine to risperidone in substance abusing individuals with schizophrenia. Am J Addict 2007 Jul-Aug; 16 (4): 260-8
46. Albanese MJ, Suh JJ. Risperidone in cocaine-dependent patients with comorbid psychiatric disorders. J Psychiatr Pract 2006 Sep; 12 (5): 306-11
47. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd ed., revised. Washington, DC: American Psychiatric Association, 1987
48. Tsuang JW, Eckman T, Marder S, et al. Can risperidone reduce cocaine use in substance abusing schizophrenic patients? J Clin Psychopharmacol 2002; 22: 629-30
49. Poling J, Kosten TR. Risperdal for substance-dependent psychotic patients. Addict Disord Treat 2005; 4: 1-3
50. Rubio G, Martinez I, Ponce G, et al. Long-acting injectable risperidone compared with zuclpenthixol in the treatment of schizophrenia with substance abuse comorbidity. Can J Psychiatry 2006; 51 (8): 531-9
51. Conley RR, Kelly DL, Gale EA. Olanzapine response in treatment-refractory schizophrenic patients with a history of substance abuse. Schizophr Res 1998; 33: 95-101
52. Littrell KH, Petty RG, Hilligoss NM, et al. Olanzapine treatment for patients with schizophrenia and substance abuse. J Subst Abuse Treat 2001; 21: 217-21
53. Potvin S, Stip E, Lipp O, et al. Quetiapine in patients with comorbid schizophrenia-spectrum and substance use disorders: an open-label trial. Curr Med Res Opinion 2006 Jul; 22 (7): 1277-85
54. Weisman RL. Quetiapine in the successful treatment of schizophrenia with comorbid alcohol and drug dependence: a case report. Int J Psychiatry Med 2003; 33 (1): 85-9
55. Beresford TP, Clapp L, Martin B, et al. Aripiprazole in schizophrenia with cocaine dependence: a pilot study. J Clin Psycopharmacol 2005; 25: 363-6
56. Brown ES, Jeffress J, Liggin JD, et al. Switching outpatients with bipolar or schizophrenic disorders and substance abuse from their current antipsychotic to aripiprazole. J Clin Psychiatry 2005; 66: 756-60
57. Buckley P. Novel antipsychotic medications and the treatment of comorbid substance abuse in schizophrenia. J Subst Abuse Treat 1998; 15 (2): 113-6
58. Tsuang JW, Eckman TE, Shaner A, et al. Clozapine for substance-abusing schizophrenic patients. Am J Psychiatry 1999; 156: 1119-20
59. Buckley P, Thompson P, Way L, et al. Substance abuse among patients with treatment resistant schizophrenia: characteristics and implications for clozapine therapy. Am J Psychiatry 1994; 151: 385-9
60. Zimmet SV, Strous RD, Burgess ES, et al. Effects of clozapine on substance use in patients with schizophrenia and schizoaffective disorder: a retrospective survey. J Clin Psychopharmacol 2000; 20: 94-8
61. Brunette MF, Drake RE, Xie H, et al. Clozapine use and relapses of substance use disorder among patients with co-occurring schizophrenia and substance use disorders. Schizophr Bull 2006; 32: 637-43
62. Lee ML. Clozapine and substance abuse in patients with schizophrenia. Can J Psychiatry 1998; 45: 855-6
63. Drake RE, Xie H, McHugo GJ, et al. The effects of clozapine on alcohol and drug use disorders among patients with schizophrenia. Schizophr Bull 2000; 26: 441-9
64. Yovell Y, Opler LA. Clozapine reverses cocaine craving in a treatment-resistant mentally ill chemical abusers: case report and hypothesis. J Nerv Ment Dis 1994; 182 (10): 591-2
65. Mueser KT, Noordsy DL, Fox L, et al. Disulfiram treatment for alcoholism in severe mental illness. Am J Addict 2003; 12: 242-52
66. Petrakis I, Poling J, Levinson C, et al. Naltrexone and disulfiram in patients with alcohol dependence and comorbid psychiatric disorders. Biol Psychiatry 2005 May 15; 57 (10): 1128-37
67. Petrakis IL, O'Malley S, Rounsaville B, et al. Naltrexone augmentation of neuroleptic treatment in alcohol abusing patients with schizophrenia. Psychopharmacology (Berl) 2004; 172: 291-7
68. Batki SL, Dimmock JA, Wade M, et al. Monitored naltrexone without counseling for alcohol abuse/dependence in schizophrenia-spectrum disorders. Am J Addict 2007 Jul-Aug; 16 (4): 253-9
69. Maxwell S. Schinderman MS. Use of naltrexone in the treatment of alcohol use disorders in patients with concomitant major mental illness. J Addict Disord 2000; 19 (3): 61-9
70. Ziedonis DM, Richardson T, Lee E, et al. Adjunctive desipramine in the treatment of cocaine abuse in schizophrenics. Psychopharmacol Bull 1992; 28: 309-14
71. DeQuardo JR, Carpenter CF, Tandon R. Patterns of substance abuse in schizophrenia: nature and significance. Psychiatr Res 1994; 28: 267-75
72. Drake RE, Fox M. Integrated treatment for dual disorders: a guide to effective practice. New York: Guilford Publications, 2003
73. President's new freedom commission on mental health, 2003 April 3 [online]. Available from URL: http://www.mentalhealthcommission.gov/reports/ reports.htm [Accessed 2005 Apr 26]
74. Center for Substance Abuse Treatment, Substance Abuse and Mental Health Services Administration (SAMHSA). Subcopharmacol stance abuse treatment for persons with co-occurring disorders. Treatment Improvement Protocol (TIP) Series 42. Rockville (MD): DHHS publication no. (SMA) 05-3922 [online]. Available from URL: http://www.ncbi.nlm.nih.gov/books/bv.fcgi?rid=hstat5.chapter.74073 [Accessed 2005 Mar 7]
75. Drake RE, McLaughlin P, Pepper B, et al. Dual diagnosis of major mental illness and substance disorder: an overview. New Dir Ment Health Serv 1991; 50: 3-12
76. Ziedonis DM. Integrated treatment of co-occurring mental illness and addiction: clinical intervention, program, and system perspectives. CNS Spectr 2004; 9: 892-904
77. Liberman RP. Psychosocial treatments for schizophrenia. Psychiatry 1994 May; 57 (2): 104-14
78. McFarlane WR, Dixon L, Lukens E, et al. Family psychoeducation and schizophrenia: a review of the literature. J Marital Fam Ther 2003 Apr; 29 (2): 223-45
79. Miller WR, Rollnick S. Motivational interviewing: preparing people to change addictive behavior. New York: Guilford, 1991
80. Ziedonis DM, Stern R. Dual recovery therapy for schizophrenia and substance abuse. Psychiatr Ann 2001; 31: 255-64
81. Ziedonis DM, George TP. Schizophrenia and nicotine use: report of a pilot smoking cessation program and review of neurobiological and clinical issues. Schizophr Bulletin 1997; 23: 247-54
82. Cuffel B, Shumway M, Chouljian T. A longitudinal study of substance use and community violence in schizophrenia. J Nerv Ment Disease 1994; 182: 704-8
83. Carey KB. Substance use reduction in the context of patient psychiatric treatment: a collaborative, motivational, harm reduction approach. Community Ment Health J 1996; 32: 291-306
84. Carey KB, Care MP, Maisto SA, et al. Brief motivational interventions for heavy college drinkers: a randomized controlled trial. J Consult Clin Psycol 2006 Oct; 74 (5): 943-54
85. Soyka M, Albus M, Immler B, et al. Psychopathology in dual diagnosis and non-addicted schizophrenics: are there differences? Eur Arch Psychiatry Clin Neurosci 2001; 251: 232-8
86. Bellack AS, Bennett ME, Gearon JS, et al. A randomized clinical trial of a new behavioral treatment for drug abuse in people with severe and persistent mental illness. Arch Gen Psychiatry 2006; 63: 426-32
87. Vogel HS, Knight E, Laudet AB, et al. Double trouble in recovery: self help for people with dual diagnosis. Psychiatr Rehabil J 1998 Mar; 21 (4): 356-64
88. United States Department of Health and Human Services, Substance Abuse and Mental Health Services Administration (SAMHSA). Matrix: populations with co-occurring substance use and mental disorders [online]. Available from URL: http://www.samhsa.gov/Matrix/matrix_cooc.aspx [Accessed 2008 Aug 26]
89. Smelson DA, Losonczy M, Castles-Fonseca K, et al. Preliminary outcomes from a booster case management program for individuals with a co-occuring substance abuse and a persistent psychiatric disorder. J Dual Diagn 2005; 3 (1): 47-59
90. Smelson DA, Losonczy M, Ziedonis D, et al. Six-month outcomes from a booster case management program for individuals with a co-occurring substance abuse and a persistent psychiatric disorder. Eur J Psychiatry 2007; 21 (2): 143-52
91. Kleber HD, Weiss RD, Anton RF, et al. Treatment of patients with substance use disorders, second edition. American Psychiatry Association. Am J Psychiatry 2007 Apr; 164 (4 Suppl.): 5-123